• Rates of cardiovascular risk factors, disease and heart attacks projected to increase significantly
• HeartBeam offers a personal, portable and easy-to-use heart-attack detection solution
• “Our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” states CEO

With heart disease consistently being the leading cause of death in the United States (https://ibn.fm/kDLwz), companies such as HeartBeam (NASDAQ: BEAT) that are focusing on solutions are gaining both attention and support. As a cardiac technology company, HeartBeam is leading the way in identifying heart attacks by developing a personal, portable and easy-to-use heart-attack detection solution.

HeartBeam’s efforts appear even more important looking forward. A recent Science Daily article (https://ibn.fm/xuLIq) reported that “by the year 2060, projected rates of cardiovascular risk factors and disease will increase significantly in the United States, according to a study published today in the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.